Biomarkers in chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 79-84

  Holler, Ernst ^a   Dickinson, Anne ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928928745     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.009     Document Type: Chapter

References (67)

1. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogateend points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81:104–107.
2. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purposemethod development and validation for successful biomarker measurement. Pharm Res. 2006;23:312–328.
3. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkersfor chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12: 126–137.
4. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis. 1993;16(Suppl 1):S22–S25.
5. Cohen J, Bayston K. Lympho`kines and the acute-phase response in clinical bone marrow transplantation. Eur Cytokine Netw. 1990;1:251–255.
6. Magalini SC, Nanni G, Agnes S, et al. Neopterin, amyloid A, C-reactive protein, gamma-interferon, and interleukin-2 receptorin diagnosis of posttransplantation rejection. Transplant Proc. 1991;23:2267–2268.
7. de Bel C, Gerritsen E, de Maaker G, Moolenaar A, Vossen J. C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation. Infection. 1991;19:92–96.
8. Sheldon J, Riches PG, Soni N, et al. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clin Chem. 1991;37:2038–2042.
9. Jarvis M, Marzolini M, Wang XN, Jackson G, Sviland L, Dickinson AM. Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft- versus- host disease. Transplantation. 2003;76:849–853.
10. Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning–an alternative target for modulation of aGvHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma. 1997;25:217–224.
11. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016.
12. Remberger M, Ringden O, Markling L. TNF alpha levels areincreased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 1995;15:99–104.
13. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol. 2003;31:1044–1050.
14. Rowbottom AW, Norton J, Riches PG, Hobbs JR, Powles RL, Sloane JP. Cytokine gene expression in skin and lymphoid organs in graft versus host disease. J Clin Pathol. 1993;46:341–345.
15. Rowbottom AW, Riches PG, Downie C, Hobbs JR. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1993;12:635–641.
16. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation. 1999;67:59–65.
17. Nakamura K, Amakawa R, Takebayashi M, et al. IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD. Bone Marrow Transplant. 2005;36:639–647.
18. Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther. 1997;39:27–32.
19. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma. 1995;17:169–173.
20. Imoto S, Oomoto Y, Murata K, et al. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease. Int J Hematol. 2000;72:92–97.
21. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant. 1996;17:1085–1092.
22. Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096–1100.
23. Kalaycioglu ME, Bolwell BJ. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Bone Marrow Transplant. 1994;14:113–115.
24. Masumoto A, Sasao T, Yoshiba F, et al. Hypereosinophilia after allogeneic bone marrow transplantation. A possible role of IL-5 overproduction by donor T-cells chronic GVHD. Rinsho Ketsueki. 1997;38:234–236.
25. Baron C, Somogyi R, Greller LD, et al. Prediction of graft-versus- host disease in humans by donor gene-expression profiling. PLoS Med. 2007;4:e23.
26. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E, on behalf of EUROBANK members. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol.2004;127:479–490.
27. Bogunia-Kubik K, Wysoczanska B, Lange A. Non-HLA gene polymorphisms and the outcome of allogeneic hematopoietic stem cell transplantation. Curr Stem Cell Res Ther. 2006;1:239–253.
28. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 2004;77:587–596.
29. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–1600.
30. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of IL-1alpha constitute independent risk factors for chronic graft versus host disease following allogeneic bone marrow transplantation. Br J Haematol. 2003;122:778–787.
31. Rocha V, Franco RF, Porcher R, et al. Host defence and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplant. Blood. 2002;100:3908–3918.
32. Kim DH, Lee NY, Sohn SK, et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation. 2005;79:1615–1622.
33. Takahashi H, Furukawa T, Hashimoto S, et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;26:1317–1323.
34. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-gamma 3/3 genotype contributes to thedevelopment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2005;90:425–426.
35. Kim DH, Jung HD, Lee NY, Sohn SK. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. Transplantation. 2007;84:917–925.
36. Shimada M, Onizuka M, Machida S, et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br J Haematol. 2007;139:458–463.
37. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood. 2006;107:2200–2207.
38. Hildebrandt GC, Granell M, Urbano-Ispizua A, et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:67–74.
39. Bunjes D, Theobald M, Nierle T, Arnold R, Heimpel H. Presence of host-specific interleukin 2-secreting T-helper cell precursors correlates closely with active primary and secondary chronic graft-versus-host disease. Bone Marrow Transplant. 1995;15:727–732.
40. Nierle T, Bunjes D, Arnold R, Heimpel H, Theobald M. Quantitative assessment of posttransplant host-specific interleukin- 2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation. Blood. 1993;81:841–848.
41. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199:1133–1142.
42. Lum LG. Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4:659–675.
43. Lum LG, Orcutt-Thordarson N, Seigneuret MC, Storb R. The regulation of Ig synthesis after marrow transplantation. IV. T4 and T8 subset function in patients with chronic graft-vs-host disease. J Immunol. 1982;129:113–119.
44. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant. 2003;32:1001–1014.
45. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458–1466.
46. Toubert A, Clave E, Talvensaari K, Douay C, Charron D. New tools in assessing immune reconstitution after hematopoietic stem cell transplantation. Vox Sang. 2000;78(Suppl 2):29–31.
47. Rieger K, Loddenkemper C, Maul J, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107:1717–1723.
48. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol. 2007;85:154–162.
49. Meignin V, Peffault de Latour R, Zuber J, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33:894–900.
50. Sanchez J, Casano J, Alvarez MA, et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2004;126:697–703.
51. Tsutsumi Y, Tanaka J, Miura Y, et al. Molecular analysis of T-cell repertoire in patients with graft-versus-host disease after allogeneic stem cell transplantation. Leuk Lymphoma. 2004;45:481–488.
52. Michalek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet. 2003;361:1183–1185.
53. Norhagen G, Engstrom PE, Bjorkstrand B, Hammarstrom L, Smith CI, Ringden O. Salivary and serum immunoglobulins in recipients of transplanted allogeneic and autologous bone marrow. Bone Marrow Transplant. 1994;14:229–234.
54. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:208–219.
55. Chan EY, Lawton JW, Lie AK, Lau CS. Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft-versus- host disease. Pathology. 1997;29:184–188.
56. Dighiero G, Intrator L, Cordonnier C, Tortevoye P, Vernant JP. High levels of anti-cytoskeleton autoantibodies are frequently associated with chronic GVHD. Br J Haematol. 1987;67:301–305.
57. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant. 1990;6:93–96.
58. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34:389–396.
59. Quaranta S, Shulman H, Ahmed A, et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol. 1999;91:106–116.
60. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation. 1988;46:238–240.
61. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus- host disease. Clin Cancer Res. 2007;13:6107–6114.
62. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:386–397.
63. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973–2978.
64. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273–277.
65. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007;109: 5511–5519.
66. Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molecular candidate for the diagnosis of graft versus host disease. Blood. 2008;111(8):4403–4412.
67. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008;111: 3276–3285.